- Home
- ELVN vs HCM Comparison
ELVN vs HCM Comparison
Compare ELVN & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELVN | HCM |
|---|---|---|
| Founded | 2016 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | 1796 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.3B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | ELVN | HCM |
|---|---|---|
| Price | $49.94 | $11.42 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 5 | 1 |
| Target Price | ★ $43.40 | $13.75 |
| AVG Volume (30 Days) | ★ 2.3M | 52.1K |
| Earning Date | 05-11-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.17 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $20.60 |
| Revenue Next Year | N/A | $15.62 |
| P/E Ratio | ★ N/A | $5.49 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.79 | $9.77 |
| 52 Week High | $52.39 | $19.50 |
Technical Indicators
Market Signals| Indicator | ELVN | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 64.02 | 57.30 |
| Support Level | $17.89 | $9.77 |
| Resistance Level | N/A | $15.59 |
| Average True Range (ATR) | 3.35 | 0.28 |
| MACD | 0.60 | 0.19 |
| Stochastic Oscillator | 80.81 | 89.30 |
Price Performance
Historical ComparisonAbout ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.